Novavax, Inc. (NVAX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 11.95 |
| Open | 11.91 |
| Bid | 11.62 x 1200 |
| Ask | 11.71 x 800 |
| Day's range | 11.43 - 12.12 |
| 52-week range | 3.53 - 23.86 |
| Volume | |
| Avg. volume | 7,872,693 |
| Market cap | 1.862B |
| Beta (5Y monthly) | 2.04 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.62 |
| Earnings date | 07 Nov 2024 - 11 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 20.00 |
Investor's Business DailyNovavax Stock Rocketed This Year, But Challenges Persist. Is It A Buy Or A Sell?
Novavax stock remains volatile. After hitting a two-year high in June on enthusiasm for its updated Covid vaccine, shares have pulled back.
ZacksBiotech Stock Roundup: NVAX Vaccine Approval, ALNY, ATHA Stock Dive on Updates & More
Novavax and Alnylam are in the spotlight following drug approval and regulatory updates, respectively.
PR NewswireNovavax to Participate in Upcoming September Conferences
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that it will participate in two upcoming investor conferences.
© 2024 Yahoo. All rights reserved.